ANGLE plc has announced the launch of its Portrait PD-L1 test, which evaluates PD-L1 protein expression on circulating tumour cells (CTCs). PD-L1 is an immune-related biomarker expressed on the surface of tumour cells that allows cancer cells to evade immune response mechanisms. The test aims to provide real-time assessment of PD-L1 status through a simple blood test, addressing the limitations of current tissue-based PD-L1 tests. The Portrait PD-L1 test is an end-to-end solution that uses ANGLE's Parsortix CTC technology to deliver minimally invasive liquid biopsy, harvest phenotypically diverse CTCs, and accurately assess PD-L1 status. The test can also monitor PD-L1 status over multiple time points, providing valuable information for patient stratification and treatment response evaluation in clinical studies. The global PD-1 and PD-L1 immunotherapy market is currently valued at $36.9 billion per annum, and the test has the potential to provide earlier insight into critical efficacy endpoints.